To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office., changes federal law or congressional policy affecting importers, exporters, and commercial firms. The main policy domain is Trade, Healthcare, Technology.
Who Benefits and How
importers, exporters, and commercial firms may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, importers, exporters, and commercial firms may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section S1: 1. Short title This Act may be cited as the Medication Affordability and Patent Integrity Act.
- Section id562F7FB98F334120975D338CAE3BC41B: 2. Disclosure of information Section 505(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) is amended by adding at the end the following:...
- Section id67CFDDC20013488281907F9506649D33: 274. Non-disclosure defense to infringement of drug patent A person shall be entitled to a defense under section 282(b) in an action asserting infringement of...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office., changes federal law or congressional policy affecting importers, exporters, and commercial firms.
Key Policy Areas
Trade, Healthcare, Technology
Primary Purpose
This bill, To require sponsors of drug applications and holders of approved applications to provide certain submissions and communications to the Food and Drug Administration and the United States Patent and Trademark Office., changes federal law or congressional policy affecting importers, exporters, and commercial firms.
Policy Domains
Whole bill
Identified Gains
- importers, exporters, and commercial firms
Identified Costs
- federal implementing agencies
- importers, exporters, and commercial firms
Sponsors
Legislative Progress
IntroducedMs. Kuster (for herself and Mrs. Harshbarger) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "secretary_of_commerce"
- → Secretary of Commerce
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology